Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs
Authors:
- 1 June 2008
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 121 (6) , 464-474
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisBMJ, 2005
- The use of NSAIDs in rheumatic disorders 2005: a global perspectiveInflammopharmacology, 2005
- Lessons from the withdrawal of rofecoxib: ***BMJ, 2004
- NSAIDs, gastroprotection and cyclo‐oxygenase‐II‐selective inhibitors*Alimentary Pharmacology & Therapeutics, 2003
- FDA warns Merck over its promotion of rofecoxibBMJ, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-Related DiseasesJournal of the American Pharmaceutical Association, 2000
- The Relationship Between Cyclooxygenase-2 Expression and Colorectal CancerJAMA, 1999
- Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1999
- RISING FREQUENCY OF ULCER PERFORATION IN ELDERLY PEOPLE IN THE UNITED KINGDOMThe Lancet, 1986